ClinicalTrials.gg
CompletedNCT02730208Updated Oct 23, 2019Results posted

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

A Phase 2 interventional study of Tezacaftor/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 9 sites in Australia. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
38th of 43
41 · median 100
Started
2016
with 5 others
Phase 2
8 of 43
none open now
Registered
10th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 38th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 10th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The primary purpose of study is to evaluate the treatment effect of tezacaftor in combination with ivacaftor (TEZ/IVA) on chest imaging endpoints using low-dose computed tomography (LDCT) at Week 72, and to evaluate the safety of TEZ/IVA through Week 72.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous for the F508del CFTR mutation
  • Confirmed diagnosis of CF
  • Percent predicted forced expiratory volume (ppFEV1) ≥70% of predicted normal for age, sex, and height during screening.
  • Stable CF disease as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug)
  • Pregnant or nursing females.
  • Sexually active subjects of who are not willing to follow the requirements.
  • Any to undergoing chest imaging, as per the site's institutional guidelines
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    TEZ/IVA

    Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.

    Drug: Tezacaftor/Ivacaftor · Drug: Ivacaftor

  • Placebo comparator
    Placebo

    Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.

    Drug: Placebo

Interventions

  • DrugTezacaftor/Ivacaftor

    Drug pages: Tezacaftor · Ivacaftor

    TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.

    Also known as: TEZ/IVA; VX-661/VX-770

  • IVA 150 mg tablet.

    Also known as: VX-770; IVA

  • DrugPlacebo

    Placebo matched to TEZ/IVA fixed-dose combination tablet.

  • DrugPlacebo

    Placebo matched to IVA tablet.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Total Brody/CF-CT Score

    The exploratory Brody/CF-CT score semi-quantitatively scores the degree of structural lung disease as shown on CT in participants with CF. The score ranges from a minimum of 0 to a maximum of 219 with higher scores indicating more severe structural lung disease.

    Time frame: From Baseline at Week 72

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 76

07

Results

Posted Aug 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneTEZ/IVAPlacebo
Started2021
Completed2020
Not completed01
Withdrew: Withdrawal of consent (not due to ae)01

Outcome measures

PrimaryAbsolute Change in Total Brody/CF-CT Score

The exploratory Brody/CF-CT score semi-quantitatively scores the degree of structural lung disease as shown on CT in participants with CF. The score ranges from a minimum of 0 to a maximum of 219 with higher scores indicating more severe structural lung disease.

Time frame:
From Baseline at Week 72
Reported as:
Least squares mean · scores on a scale
Absolute Change in Total Brody/CF-CT Score
scores on a scaleTEZ/IVAPlacebo
Absolute Change in Total Brody/CF-CT Score0.90 ± 2.092.38 ± 2.07
Statistical analysis
  • TEZ/IVA vs Placebo · Least squares (ls) mean difference: -1.48 · 95% CI -7.47 to 4.52
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 76
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTEZ/IVAPlacebo
Participants with AEs2021
Participants with SAEs813

Adverse events

Collected over Day 1 up to Week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEZ/IVA0/20 (0%)8/20 (40%)19/20 (95%)
Placebo0/21 (0%)13/21 (61.9%)20/21 (95.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTEZ/IVAPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations5/206/21
Lung infection pseudomonalInfections and infestations2/200/21
Atrioventricular block first degreeCardiac disorders1/200/21
Abdominal pain upperGastrointestinal disorders1/200/21
Testicular torsionReproductive system and breast disorders1/200/21
Atypical mycobacterial lower respiratory tract infectionInfections and infestations0/201/21
GastroenteritisInfections and infestations0/201/21
Abdominal painGastrointestinal disorders0/201/21
VomitingGastrointestinal disorders0/201/21
Hepatic cirrhosisHepatobiliary disorders0/201/21
Most frequent other events
Showing 10 of 30
Most frequent other events
EventTEZ/IVAPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations5/209/21
CoughRespiratory, thoracic and mediastinal disorders8/209/21
Bacterial test positiveInvestigations0/205/21
Upper respiratory tract infectionInfections and infestations4/202/21
HaemoptysisRespiratory, thoracic and mediastinal disorders4/202/21
Productive coughRespiratory, thoracic and mediastinal disorders4/204/21
HeadacheNervous system disorders1/204/21
NauseaGastrointestinal disorders0/204/21
Lower respiratory tract infection bacterialInfections and infestations3/202/21
NasopharyngitisInfections and infestations3/201/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)TEZ/IVAPlaceboTotal
Mean20.4 ± 7.520.1 ± 9.320.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)TEZ/IVAPlaceboTotal
Female111021
Male91120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TEZ/IVAPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino202141
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TEZ/IVAPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202141
More than one race000
Unknown or Not Reported000
Total Brody/Cystic Fibrosis - Computed Tomography (CF-CT) Score
Total Brody/Cystic Fibrosis - Computed Tomography (CF-CT) Score(scores on a scale)TEZ/IVAPlaceboTotal
Mean38.29 ± 22.9143.68 ± 33.9640.98 ± 28.72
08

Study locations

9 sites
  • Chermside, Australia
  • Melbourne, Australia
  • Nedlands, Australia
  • New Lambton Heights, Australia
  • Parkville SIC, Australia
  • Randwick, Australia
  • South Brisbane, Australia
  • Subiaco, Australia
  • Westmead, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jul 2018, 22 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 22 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 6, 2016
StartActual
Sep 2016
Primary completionActual
Jul 2018
CompletionActual
Jul 2018
Results first posted
Aug 21, 2019
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02730208
Responsible party
Sponsor
First posted
Apr 6, 2016
Start date
Sep 2016
Primary completion
Jul 2018
Completion
Jul 2018
Results posted
Aug 21, 2019
Last update
Oct 23, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion